コンテンツへスキップ
Merck

Irritable bowel syndrome--diarrhoea.

Best practice & research. Clinical gastroenterology (2013-02-07)
Arnold Wald
要旨

IBS is a functional gastrointestinal disorder which has been subtyped according to bowel habits. This review presents recommendations for IBS-D which makes up about 1/3 of all patients and which is defined as IBS with loose or watery stools with ≥25% of bowel movements. Because IBS is a complex biopsychosocial illness, treatment cannot and should not be directed only to altered bowel habits. Evidence will be presented for dietary manipulations, probiotics and pharmacotherapies including tricyclic agents, antibiotics, serotonin antagonists and anti-diarrhoeal agents in the management of patients with IBS-D.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ロペラミド 塩酸塩
Supelco
ロペラミド 塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
ロペラミド 塩酸塩, European Pharmacopoeia (EP) Reference Standard
Supelco
ロペラミド 塩酸塩, VETRANAL®, analytical standard